Studieoverzicht
BOOG nr.: |
Status: ( Open )
|
Indication: ( View all )
|
Subindication: |
Menopausal status: |
2022-04 NABOR | Open | Data registration | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2022-02 DESCARTES | Open | Locoregional | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2022-01 DIRECT-2 | Open | Neoadjuvant | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2021-03 EMBER-3 | Open | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2021-01 SEQUEL-Breast | Open | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2019-01 TIBET | Open | Advanced/metastatic | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2014-04 LORD | Open | Locoregional | Not applicable | Both pre- and postmenopausal |